Skip to main content
George Demetri, MD, Oncology, Boston, MA

GeorgeDDemetriMD

Oncology Boston, MA

Hematologic Oncology, Melanoma, Sarcoma

Professor of Medicine, Harvard Medical School and Director, Ludwig Center at Harvard; Director, Sarcoma Center, Dana-Farber/Brigham and Women's Cancer Center

Dr. Demetri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Demetri's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Dana-Farber Cancer Institute
    Boston, MA 02215
    Phone+1 617-632-5204
    Fax+1 617-632-3408

Summary

  • Dr. George Demetri is an oncologist in Boston, MA and is affiliated with multiple hospitals affiliated with Harvard Medical School in the area, primarily the Dana-Farber Cancer Institute. He received his medical degree from Stanford University School of Medicine and has been in practice 34 years. He specializes in Sarcomas and Developmental Therapeutics
    .

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1983 - 1985
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • MA State Medical License
    MA State Medical License 1986 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow (FASCO) American Society of Clinical Oncologists, 2008
  • Super Doctor SuperDoctors.com
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors. 
    2019 ASCO Annual Meeting - 6/1/2019

Other

Press Mentions

  • For New NCI Director, Work Turns Personal: She Is Diagnosed with Cancer
    For New NCI Director, Work Turns Personal: She Is Diagnosed with CancerDecember 14th, 2022
  • Cancer Combination Therapy Company IDRx Launches with $122M Series a Funding
    Cancer Combination Therapy Company IDRx Launches with $122M Series a FundingAugust 2nd, 2022
  • Sylvester’s Outstanding Faculty for 2022: In Their Own Words
    Sylvester’s Outstanding Faculty for 2022: In Their Own WordsJuly 15th, 2022
  • Join now to see all

Grant Support

  • Targeted Therapy Resistance Mechanisms In Gastrointestinal Stromal Tumor(Gist)National Cancer Institute2007–2011

Professional Memberships